JP2016507066A - 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 - Google Patents

多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 Download PDF

Info

Publication number
JP2016507066A
JP2016507066A JP2015557128A JP2015557128A JP2016507066A JP 2016507066 A JP2016507066 A JP 2016507066A JP 2015557128 A JP2015557128 A JP 2015557128A JP 2015557128 A JP2015557128 A JP 2015557128A JP 2016507066 A JP2016507066 A JP 2016507066A
Authority
JP
Japan
Prior art keywords
fragment
biological sample
bcma
subject
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015557128A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507066A5 (cg-RX-API-DMAC7.html
Inventor
ジェイムズ アール． ベレンソン，
ジェイムズ アール． ベレンソン，
ハイミン チェン，
ハイミン チェン，
エリック サンチェス，
エリック サンチェス，
Original Assignee
インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ
インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ, インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ filed Critical インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ
Publication of JP2016507066A publication Critical patent/JP2016507066A/ja
Publication of JP2016507066A5 publication Critical patent/JP2016507066A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2015557128A 2013-02-08 2014-02-07 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 Withdrawn JP2016507066A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361762753P 2013-02-08 2013-02-08
US61/762,753 2013-02-08
PCT/US2014/015338 WO2014124280A1 (en) 2013-02-08 2014-02-07 Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018090456A Division JP2018136344A (ja) 2013-02-08 2018-05-09 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法

Publications (2)

Publication Number Publication Date
JP2016507066A true JP2016507066A (ja) 2016-03-07
JP2016507066A5 JP2016507066A5 (cg-RX-API-DMAC7.html) 2017-03-09

Family

ID=51300158

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015557128A Withdrawn JP2016507066A (ja) 2013-02-08 2014-02-07 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法
JP2018090456A Pending JP2018136344A (ja) 2013-02-08 2018-05-09 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018090456A Pending JP2018136344A (ja) 2013-02-08 2018-05-09 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法

Country Status (5)

Country Link
US (2) US10126301B2 (cg-RX-API-DMAC7.html)
EP (1) EP2954330A4 (cg-RX-API-DMAC7.html)
JP (2) JP2016507066A (cg-RX-API-DMAC7.html)
CA (1) CA2900529A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014124280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2954330A4 (en) 2013-02-08 2016-08-31 Inst Myeloma & Bone Cancer Res IMPROVED DIAGNOSTIC, PROGNOSTIC AND MONITORING METHODS FOR MULTIPLE MYELOMA, CHRONIC LYMPHOCYTIC LEUKEMIA AND NON-HODGKIN LYMPHOMA B-CELL LYMPHOMA
KR20180077193A (ko) 2015-10-30 2018-07-06 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 예후 방법
DK3402515T3 (da) 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
US20200326339A1 (en) 2016-05-16 2020-10-15 James Richard BERENSON Improved methods for monitoring immune status of a subject
EP3582782B1 (en) 2017-02-17 2023-06-07 Fred Hutchinson Cancer Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3589952A4 (en) * 2017-02-28 2021-03-10 Menarini Silicon Biosystems S.p.A. IMPROVED KITS AND TESTS FOR DETECTING CIRCULATING MULTIPLE MYELOMA CELLS FROM BLOOD
WO2018231944A1 (en) 2017-06-13 2018-12-20 Berenson James R Diagnostic, prognostic, and monitoring methods for solid tumor cancers
ES2644580B2 (es) * 2017-07-26 2018-06-04 Universitat Politècnica De València Procedimiento de diagnóstico de lupus eritematoso sistémico (les)
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019090364A1 (en) 2017-11-06 2019-05-09 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN112384531B (zh) 2018-06-01 2024-05-14 诺华股份有限公司 针对bcma的结合分子及其用途
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
ES2983797T3 (es) * 2018-08-31 2024-10-24 Hoffmann La Roche Timidina cinasa (TK-1) en índices pronóstico para LDLBG
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
JOP20210309A1 (ar) 2019-05-21 2023-01-30 Novartis Ag جزيئات ربط بـ cd19 واستخدامتها
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
CN117305458B (zh) * 2023-10-20 2024-06-21 四川省医学科学院·四川省人民医院 TKTmRNA检测试剂在制备多发性骨髓瘤筛查试剂盒中的用途及试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207474A1 (en) * 2005-11-01 2007-09-06 Ansell Stephen M PROMOTER POLYMORPHISMS OF THE BLyS GENE AND USE IN DIAGNOSTIC METHODS
WO2012143498A1 (en) * 2011-04-21 2012-10-26 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
WO2012163805A1 (en) * 2011-05-27 2012-12-06 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
WO1998001151A1 (en) 1996-07-10 1998-01-15 Meiji Milk Products Co., Ltd. Novel use of mk family as hematopoietic factor
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US20040002068A1 (en) * 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2002068414A2 (en) 2001-02-27 2002-09-06 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
JP2005527473A (ja) 2001-09-06 2005-09-15 バイオジェン アイデック エムエー インコーポレイテッド Ｂａｆｆの結晶構造および製薬におけるその用途
CA2523776A1 (en) 2003-03-07 2004-09-23 Xencor, Inc. Baff mutants with at least one amino acid substitution and methods of their production
WO2006025345A1 (ja) 2004-08-31 2006-03-09 Kowa Company, Ltd. 抗ヒトｂａｆｆ抗体
CA2583900A1 (en) 2004-10-13 2006-04-27 The Washington University Use of baff to treat sepsis
AU2005318086B2 (en) 2004-12-23 2011-07-07 Merck Serono Sa BCMA polypeptides and uses thereof
ATE500275T1 (de) * 2005-09-26 2011-03-15 Enzo Life Sciences Els Ag Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
WO2007056288A2 (en) * 2005-11-08 2007-05-18 Biogen Idec Ma Inc. Methods of evaluating baff
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
SI2455382T1 (sl) 2005-12-13 2017-03-31 Incyte Holdings Corporation S heteroarilom substituirani pirolo(2,3b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janus kinaze
WO2007100895A2 (en) 2006-02-27 2007-09-07 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
AU2007248019B2 (en) 2006-05-03 2012-10-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric T cell receptors and related materials and methods of use
ES2467665T5 (es) 2007-06-13 2022-11-03 Incyte Holdings Corp Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
WO2009132058A2 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
DK2406284T5 (en) 2009-03-10 2017-06-12 Biogen Ma Inc ANTI-BCMA ANTIBODIES
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
JP6694712B2 (ja) 2012-11-01 2020-05-20 マックス−デルブルック−セントラム フアー モレキュラーレ メデジン Ｃｄ２６９（ｂｃｍａ）に対する抗体
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP2954330A4 (en) 2013-02-08 2016-08-31 Inst Myeloma & Bone Cancer Res IMPROVED DIAGNOSTIC, PROGNOSTIC AND MONITORING METHODS FOR MULTIPLE MYELOMA, CHRONIC LYMPHOCYTIC LEUKEMIA AND NON-HODGKIN LYMPHOMA B-CELL LYMPHOMA
JP2017503001A (ja) 2014-01-20 2017-01-26 ギリアード サイエンシーズ， インコーポレイテッド がんを処置するための療法
NZ725701A (en) 2014-04-30 2023-09-29 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Humanized antibodies against cd269 (bcma)
EP3148545B1 (en) 2014-05-28 2023-03-15 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
EP3154596A4 (en) 2014-06-10 2018-01-24 Institute for Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
RS63364B1 (sr) 2014-08-11 2022-07-29 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
EP4310097A3 (en) 2014-12-05 2024-04-03 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
ES2883249T3 (es) 2015-03-17 2021-12-07 Mayo Found Medical Education & Res Métodos y materiales para evaluar y tratar el cáncer
JP7178902B2 (ja) 2015-07-24 2022-11-28 オンコトラッカー， インコーポレイテッド 免疫系の機能不全の治療のためのガンマセクレターゼモジュレーター
HRP20201375T1 (hr) 2015-08-17 2020-11-27 Janssen Pharmaceutica Nv ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE
KR20180077193A (ko) 2015-10-30 2018-07-06 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 예후 방법
DK3402515T3 (da) 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
US20200326339A1 (en) 2016-05-16 2020-10-15 James Richard BERENSON Improved methods for monitoring immune status of a subject
AU2017306267A1 (en) 2016-08-01 2019-02-14 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-M2 macrophage molecule
WO2018085363A2 (en) 2016-11-02 2018-05-11 Berenson James Richard Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma
WO2018231944A1 (en) 2017-06-13 2018-12-20 Berenson James R Diagnostic, prognostic, and monitoring methods for solid tumor cancers
JP2020528885A (ja) 2017-07-19 2020-10-01 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
EP3873478A4 (en) 2018-10-31 2022-08-10 Oncotracker, Inc. METHOD OF IMPROVING IMMUNE-BASED THERAPY

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207474A1 (en) * 2005-11-01 2007-09-06 Ansell Stephen M PROMOTER POLYMORPHISMS OF THE BLyS GENE AND USE IN DIAGNOSTIC METHODS
WO2012143498A1 (en) * 2011-04-21 2012-10-26 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
WO2012163805A1 (en) * 2011-05-27 2012-12-06 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERIC SANCHEZ,ET AL.: "Serum B-cell maturation antigen is elevated in multiole myeloma and correlates with disease status a", BRITISH JOURNAL OF HAEMATOLOGY, vol. Volume 158, Issue 6, JPN7017003662, 18 July 2012 (2012-07-18), pages 727 - 738, ISSN: 0003679709 *
JEROME MOREAUX,ET AL.: "BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamet", BLOOD, vol. VOLUME 103,NUMBER 8, JPN7017003663, 15 April 2004 (2004-04-15), pages 3147 - 3157, ISSN: 0003679710 *

Also Published As

Publication number Publication date
EP2954330A4 (en) 2016-08-31
US12174189B2 (en) 2024-12-24
WO2014124280A1 (en) 2014-08-14
EP2954330A1 (en) 2015-12-16
US20190107541A1 (en) 2019-04-11
US10126301B2 (en) 2018-11-13
JP2018136344A (ja) 2018-08-30
CA2900529A1 (en) 2014-08-14
US20160131654A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
US12174189B2 (en) Diagnostic, prognostic, and monitoring methods for chronic lymphocytic leukemia
JP2022058619A (ja) 被験体の免疫状態をモニタリングするための改善された方法
EP3458853B1 (en) Improved methods for monitoring immune status of a subject
EP3639028B1 (en) Diagnostic, prognostic, and monitoring methods for breast cancer
EP2551673B1 (en) Methods for the detection of cancer infiltration of the central nervous system
ES2939143T3 (es) Biomarcadores para una politerapia que comprende lenvatinib y everolimus
WO2018085363A2 (en) Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma
HK40082699A (en) Improved methods for monitoring immune status of a subject
CA3010019C (en) Improved methods for monitoring immune status of a subject
EP3832309A1 (en) Composition for diagnosis of bone metastasis of cancer and kit comprising same
HK40000182B (en) Improved methods for monitoring immune status of a subject
HK40007456B (en) Improved methods for monitoring immune status of a subject
HK40007456A (en) Improved methods for monitoring immune status of a subject
KR101567053B1 (ko) 방사선 피폭에 의한 간 손상 예측용 바이오마커 및 그 예측방법
CN112639475A (zh) Dlbcl的预后指数中的胸苷激酶(tk-1)
JP6195716B2 (ja) 抗癌剤耐性診断マーカー
WO2025121385A1 (ja) Ｔ細胞関連疾患の病態、予後及び治療効果の予測技術
WO2010062705A1 (en) Cancer diagnosis using ki-67
KR20180099722A (ko) 예측 방법 및 상기 방법에 유용한 키트

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180405

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180809